Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$177.31
-0.4%
$167.02
$140.68
$181.16
$426.92B0.48.95 million shs2.91 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$734.09
-0.2%
$747.03
$623.78
$954.00
$694.75B0.474.15 million shs1.16 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.45
-1.2%
$82.32
$73.31
$120.30
$210.84B0.3715.21 million shs6.10 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.86
+4.6%
$9.59
$8.01
$22.42
$2.56B0.64.44 million shs1.99 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.40%+0.67%+6.26%+15.92%+7.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.29%-0.05%-3.53%-4.20%-23.48%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.44%+0.24%+7.66%+9.02%-27.95%
Organon & Co. stock logo
OGN
Organon & Co.
+0.11%+3.58%-3.64%-1.42%-57.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.6089 of 5 stars
2.33.04.23.92.91.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5 of 5 stars
4.33.03.34.02.63.33.8
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9971 of 5 stars
3.24.05.04.23.01.73.8
Organon & Co. stock logo
OGN
Organon & Co.
4.8008 of 5 stars
3.33.01.73.72.21.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.65
Moderate Buy$176.29-0.57% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.67
Moderate Buy$950.1729.44% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.35
Hold$107.4427.22% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0082.61% Upside

Current Analyst Ratings Breakdown

Latest MRK, LLY, OGN, HARP, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$675.00 ➝ $700.00
8/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
8/21/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$185.00 ➝ $200.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$700.00
8/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/13/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$975.00 ➝ $825.00
8/13/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$942.00 ➝ $875.00
8/11/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,010.00 ➝ $900.00
8/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,050.00 ➝ $895.00
8/7/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.81$13.13 per share13.50$32.58 per share5.44
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.42$14.26 per share51.47$19.39 per share37.86
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$63.62B3.32$9.50 per share8.89$19.64 per share4.30
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.40$5.16 per share1.91$2.82 per share3.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3518.9616.022.2625.00%32.49%13.00%10/21/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3047.9823.591.0225.91%92.72%16.89%10/29/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4913.018.530.8925.79%41.05%16.55%10/30/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.693.662.640.8611.15%163.88%6.99%10/30/2025 (Estimated)

Latest MRK, LLY, OGN, HARP, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.93%N/A55.61%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.82%N/A39.22%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.84%N/A49.92%14 Years
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.81%N/A2.97%N/A

Latest MRK, LLY, OGN, HARP, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.97%9/15/20259/15/202510/7/2025
8/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.9%8/15/20258/15/20259/11/2025
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17
Organon & Co. stock logo
OGN
Organon & Co.
11.98
1.65
1.13

Institutional Ownership

CompanyInstitutional Ownership
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
74.01%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.13 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.50 billionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.97 million256.33 millionNot Optionable

Recent News About These Companies

Northern Trust Corp Grows Position in Organon & Co. $OGN
Head-To-Head Comparison: Organon & Co. (NYSE:OGN) vs. DocGo (NASDAQ:DCGO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$177.30 -0.76 (-0.42%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$734.09 -1.10 (-0.15%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$84.45 -1.03 (-1.20%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.86 +0.44 (+4.64%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.